Of relevance to the present study, recent data indicated that in patients with psoriasis IL-17 and IL-22 producing cells are in a substantial proportion CD3- innate lymphoid cells (ILC), and adalimumab treatment decreased the percentages of circulating NKp44+ILC3 [48]. The gene discussed is IL22; the disease is psoriasis.